Platelet protein

"Platelet protein" is a non-specific, non-canonical term that refers to the collective proteome of blood platelets rather than a single molecular target. Research has identified over 5,000 distinct proteins within human platelets, which are essential for physiological processes such as hemostasis, thrombus formation, and the modulation of the immune response [1, 2]. In clinical pharmacology, the term is often used as a broad descriptor for established therapeutic targets located on or within platelets, such as cyclooxygenase-1 (COX-1), the P2Y12 purinergic receptor, and the integrin alpha-IIb/beta-3 (glycoprotein IIb/IIIa) [3, 5]. These proteins are the sites of action for major antiplatelet drugs like aspirin, clopidogrel, and abciximab, respectively, which are used to prevent cardiovascular events [5, 12]. Additionally, specific secreted proteins like Platelet Factor 4 (CXCL4) and Platelet Basic Protein (CXCL7) are highly abundant and serve as critical mediators in conditions like heparin-induced thrombocytopenia and inflammatory signaling [6, 11]. Because the term lacks molecular precision and represents an entire cell's protein content, it is considered "incorrect" or overly broad for use as a specific target designation in structured drug development databases [1, 14].

Other names

Platelet proteomePlatelet-derived proteinsThrombocyte proteins

Inhibition of platelet activation and aggregation via multiple specific mechanisms, including irreversible inhibition of cyclooxygenase-1 (COX-1), antagonism of the P2Y12 adenosine diphosphate (ADP) receptor, and blockade of the integrin alpha-IIb/beta-3 (glycoprotein IIb/IIIa) receptor.